The role of FLT3 in haematopoietic malignancies

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2001) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,721 · see citing works

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Thiede, C., Steudel, C., Mohr, B., Schaich, M. A., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,719 · see citing works

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,554 · see citing works

Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162 · see citing works

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,151 · see citing works

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., & McKenna, H. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.5.1953 · Cited by 1,117 · see citing works

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C. M., Serve, H. L., Büchner, T., et al. (2002) · Blood · doi:10.1182/blood.v100.1.59 · Cited by 972 · see citing works

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Druker, B. J., & Lydon, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 881 · see citing works

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

O'Farrell, A. M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 865 · see citing works

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 747 · see citing works

c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities

Lyman, S. D., & Jacobsen, S. E. W. (1998) · Blood · doi:10.1182/blood.v91.4.1101 · Cited by 686 · see citing works

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Whitman, S. P., Archer, K. J., Lin, F., Baldus, C. D., Becknell, B., Carlson, B. D., Carroll, A. J., Mrózek, K., Vardiman, J., George, S. L., et al. (2001) · PubMed · Cited by 633 · see citing works

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Weisberg, E., Boulton, C. L., Kelly, L. M., Manley, P. W., Fabbro, D., Meyer, T., Gilliland, D. G., & Griffin, J. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00069-7 · Cited by 603 · see citing works

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways

Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Müller‐Tidow, C., Grüning, W., Kratz‐Albers, K., Serve, S., Steur, C., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3907 · Cited by 599 · see citing works

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D., & Lemischka, I. R. (1991) · Cell · doi:10.1016/0092-8674(91)90010-v · Cited by 593 · see citing works

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., & Naoe, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203354 · Cited by 579 · see citing works

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

Mackarehtschian, K., Hardin, J. D., Moore, K., Boast, S., Goff, S. P., & Lemischka, I. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90167-1 · Cited by 575 · see citing works

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

Fong, L. H., Hou, Y., Rivas, A., Benike, C. J., Yuen, A. R., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 540 · see citing works

Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells

Lyman, S. D., James, L., Bos, T. V., de Vries, P., Brasel, K., Gliniak, B., Hollingsworth, L. T., Picha, K. S., McKenna, H. J., Splett, R. R., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90325-k · Cited by 521 · see citing works

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

Meshinchi, S., Woods, W. G., Stirewalt, D. L., Sweetser, D. A., Buckley, J. D., Tjoa, T. K., Bernstein, I. D., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.1.89 · Cited by 516 · see citing works

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

Kelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G. (2002) · Blood · doi:10.1182/blood.v99.1.310 · Cited by 487 · see citing works

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Levis, M. J., Allebach, J., Tse, K.-F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones‐Bolin, S., Ruggeri, B., Dionne, C. A., & Small, D. (2002) · Blood · doi:10.1182/blood.v99.11.3885 · Cited by 472 · see citing works

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

Hannum, C. H., Culpepper, J., Campbell, D., et al. (1994) · Nature · doi:10.1038/368643a0 · Cited by 456 · see citing works

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

Kiyoi, H., Towatari, M., Yokota, S., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401130 · Cited by 455 · see citing works

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 454 · see citing works

A PMLRAR α transgene initiates murine acute promyelocytic leukemia

Brown, D. E., Kogan, S. C., Lagasse, E., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2551 · Cited by 452 · see citing works

Switching Signals On or Off by Receptor Dimerization

Weiss, A., & Schlessinger, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81469-5 · Cited by 431 · see citing works

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M. Z., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.459 · Cited by 429 · see citing works

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia

Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 429 · see citing works

Inhibition of FLT3 in MLL

Armstrong, S. A., Kung, A. L., Mabon, M. E., Silverman, L. B., Stam, R. W., den Boer, M. L., Pieters, R., Kersey, J. H., Sallan, S. E., Fletcher, J. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00003-5 · Cited by 396 · see citing works

Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia

Abu‐Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R., & Reilly, J. T. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02850.x · Cited by 388 · see citing works

Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RARα Under Control of Cathepsin G Regulatory Sequences

Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G., et al. (1997) · Blood · doi:10.1182/blood.v89.2.376 · Cited by 366 · see citing works

Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma.

Knudson, A. G., Hethcote, H. W., & Brown, B. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.12.5116 · Cited by 351 · see citing works

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia

Kiyoi, H., Naoe, T., Yokota, S., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400756 · Cited by 344 · see citing works

Expression of the hematopoietic growth factor receptor FLT3 (STK- 1/Flk2) in human leukemias

Carow, C. E., Levenstein, M. E., Kaufmann, S. H., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M. J., Civin, C., & Small, D. (1996) · Blood · doi:10.1182/blood.v87.3.1089.bloodjournal8731089 · Cited by 343 · see citing works

Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells

Rosnet, O., Schiff, C., Pébusque, M., et al. (1993) · Blood · doi:10.1182/blood.v82.4.1110.1110 · Cited by 342 · see citing works

PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model

Kelly, L. M., Kutok, J. L., Williams, I. R., Boulton, C. L., Amaral, S. M., Curley, D. P., Ley, T. J., & Gilliland, D. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122233699 · Cited by 320 · see citing works

Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells

Lyman, S. D., James, L., Johnson, L., et al. (1994) · Blood · doi:10.1182/blood.v83.10.2795.2795 · Cited by 316 · see citing works

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

Lynch, D. H., Andreasen, A., Maraskovsky, E., et al. (1997) · Nature Medicine · doi:10.1038/nm0697-625 · Cited by 314 · see citing works

B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.

Nadler, L. M., Korsmeyer, S. J., Anderson, K. C., et al. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111428 · Cited by 311 · see citing works

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

Shih, L., Huang, C., Wu, J., Lin, T., Dunn, P., Wang, P., Kuo, M., Lai, C., & Hsu, H.-C. (2002) · Blood · doi:10.1182/blood-2002-01-0195 · Cited by 307 · see citing works

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)

Kelly, L. M., Yu, J., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I. R., Amaral, S. M., Curley, D. P., Duclos, N., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00070-3 · Cited by 305 · see citing works

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

Abuduhier, F. M., Goodeve, A. C., Wilson, G. A., Gari, M. A., Peake, I. R., Rees, D. C., Vandenberghe, E., Winship, P. R., & Reilly, J. T. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02317.x · Cited by 304 · see citing works

C-kit mutations in core binding factor leukemias

Beghini, A., Peterlongo, P., Ripamonti, C. B., et al. (2000) · Blood · doi:10.1182/blood.v95.2.726 · Cited by 301 · see citing works

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

Mizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298 · see citing works

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2195 · Cited by 293 · see citing works

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

Kiyoi, H., Ohno, R., Ueda, R., Saito, H., & Naoe, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205332 · Cited by 292 · see citing works

Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates

Bustelo, X. R., Ledbetter, J. A., & Barbacid, M. (1992) · Nature · doi:10.1038/356068a0 · Cited by 291 · see citing works

Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family.

Rosnet, O., Marchetto, S., deLapeyrière, O., & Birnbaum, D. (1991) · PubMed · Cited by 287 · see citing works

Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.

Rosnet, O., Bühring, H. ‐., Marchetto, S., et al. (1996) · PubMed · Cited by 250 · see citing works

Dendritic Cell Development in Culture from Thymic Precursor Cells in the Absence of Granulocyte/Macrophage Colony-stimulating Factor

Saunders, D., Lucas, K., Ismaili, J., Wu, L., Maraskovsky, E., Dunn, A. R., & Shortman, K. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2185 · Cited by 248 · see citing works

Involvement of the B-lymphoid system in chronic myelogenous leukaemia

Martin, P. J., Najfeld, V., Hansen, J. A., Penfold, G. K., Jacobson, R. J., & Fialkow, P. J. (1980) · Nature · doi:10.1038/287049a0 · Cited by 235 · see citing works

Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer.

Chakravarty, P. K., Alfieri, A. A., Thomas, E. K., Beri, V., Tanaka, K. E., Vikram, B., & Guha, C. (1999) · PubMed · Cited by 218 · see citing works

Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors

Gabbianelli, M., Pelosi, E., Montesoro, E., Valtieri, M., Luchetti, L., Samoggia, P., Vitelli, L., Barberi, T., Testa, U., & Lyman, S. D. (1995) · Blood · doi:10.1182/blood.v86.5.1661.bloodjournal8651661 · Cited by 218 · see citing works

Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation

Tsujimura, T., Furitsu, T., Morimoto, M., Isozaki, K., Nomura, S., Matsuzawa, Y., Kitamura, Y., & Kanakura, Y. (1994) · Blood · doi:10.1182/blood.v83.9.2619.2619 · Cited by 212 · see citing works

Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro

Shah, A. J., Smogorzewska, E. M., Hannum, C. H., & Crooks, G. (1996) · Blood · doi:10.1182/blood.v87.9.3563.bloodjournal8793563 · Cited by 212 · see citing works

Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400770 · Cited by 209 · see citing works

Essential Role of Signal Transducer and Activator of Transcription (Stat)5a but Not Stat5b for Flt3-Dependent Signaling

Zhang, S., Fukuda, S., Lee, Y., Hangoc, G., Cooper, S. H., Spolski, R. J., Leonard, W. J., & Broxmeyer, H. E. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.719 · Cited by 207 · see citing works

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Giles, F. J., Stopeck, A., Silverman, L. R., Lancet, J. E., Cooper, M. A., Hannah, A. L., Cherrington, J. M., O'Farrell, A. M., Yuen, H. A., Louie, S. G., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3023 · Cited by 201 · see citing works

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

Levis, M. J., Tse, K.-F., Smith, B. D., et al. (2001) · Blood · doi:10.1182/blood.v98.3.885 · Cited by 189 · see citing works

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol

Noguera, N., Breccia, M., Divona, M., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402723 · Cited by 183 · see citing works

A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration

Gille, H., Kowalski, J., Yu, L., Chen, H., Pisabarro, M. T., Davis-Smyth, T., & Ferrara, N. (2000) · The EMBO Journal · doi:10.1093/emboj/19.15.4064 · Cited by 180 · see citing works

Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

Sabbath, K. D., Ball, E. D., Larcom, P., Davis, R. B., & Griffin, J. D. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111756 · Cited by 180 · see citing works

Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children

Xu, F., Taki, T., Yang, H. W., Hanada, R., Hongo, T., Ohnishi, Kobayashi, M., Bessho, F., Yanagisawa, M., & Hayashi, Y. (1999) · British Journal of Haematology · doi:10.1111/j.1365-2141.1999.01284.x · Cited by 176 · see citing works

Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia

Iwai, T., Yokota, S., Nakao, M., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401241 · Cited by 174 · see citing works

Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.

Dosil, M., Wang, S., & Lemischka, I. R. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6572 · Cited by 165 · see citing works

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Yee, K. W. H., O'Farrell, A. M., Smolich, B. D., Cherrington, J. M., McMahon, G., Wait, C. L., McGreevey, L. S., Griffith, D., & Heinrich, M. C. (2002) · Blood · doi:10.1182/blood-2002-02-0531 · Cited by 164 · see citing works

N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance

Radich, J., Kopecky, K., Willman, C., et al. (1990) · Blood · doi:10.1182/blood.v76.4.801.801 · Cited by 159 · see citing works

FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells

Turner, A., Lin, N., Issarachai, S. S., Lyman, S. D., & Broudy, V. (1996) · Blood · doi:10.1182/blood.v88.9.3383.bloodjournal8893383 · Cited by 154 · see citing works

Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia

Meshinchi, S., Stirewalt, D. L., Alonzo, T. A., Zhang, Q., Sweetser, D. A., Woods, W. G., Bernstein, I. D., Arceci, R. J., & Radich, J. P. (2003) · Blood · doi:10.1182/blood-2003-01-0137 · Cited by 146 · see citing works

Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children

Smith, M. T., Wang, Y., Skibola, C. F., Slater, D. J., Nigro, L. L., Nowell̀, P. C., Lange, B. J., & Felix, C. A. (2002) · Blood · doi:10.1182/blood-2001-12-0264 · Cited by 141 · see citing works

Mechanism of kit ligand, phorbol ester, and calcium-induced down-regulation of c-kit receptors in mast cells

Yee, N. S., Langen, H., & Besmer, P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85226-2 · Cited by 137 · see citing works

Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax

Lisovsky, M. Y., Estrov, Z. E., Zhang, X., Consoli, U., Sanchez‐Williams, G., Snell, V., Munker, R., Goodacre, A., Vg, S., & Andreeff, M. (1996) · Blood · doi:10.1182/blood.v88.10.3987.bloodjournal88103987 · Cited by 136 · see citing works

Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer

Morse, M. A., Nair, S. K., Fernandez-Casal, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3883 · Cited by 130 · see citing works

The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro

Rusten, L., Lyman, S. D., Veiby, O., & Jacobsen, S. E. W. (1996) · Blood · doi:10.1182/blood.v87.4.1317.bloodjournal8741317 · Cited by 129 · see citing works

Expression of the flt3 receptor and its ligand on hematopoietic cells.

Brasel, K., Escobar, S., Anderberg, R., et al. (1995) · PubMed · Cited by 125 · see citing works

Hematopoietic receptors of class III receptor-type tyrosine kinases.

Rosnet, O., & Birnbaum, D. (1993) · PubMed · Cited by 119 · see citing works

Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.

Meierhoff, G., Dehmel, U., Gruss, H. J., et al. (1995) · PubMed · Cited by 117 · see citing works

Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.

Chen, K. Z. M., Braun, S., Lyman, S. D., et al. (1997) · PubMed · Cited by 117 · see citing works

Flt3 Ligand Induces Tyrosine Phosphorylation of Gab1 and Gab2 and Their Association with Shp-2, Grb2, and PI3 Kinase

Zhang, S., & Broxmeyer, H. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3662 · Cited by 117 · see citing works

Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells

Zhang, S., Mantel, C., & Broxmeyer, H. E. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.3.372 · Cited by 114 · see citing works

Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia

Lyman, S. D., Seaberg, M. A., Hanna, R., Zappone, J., Brasel, K., Abkowitz, J., Prchal, J., Schultz, J., & Shahidi, N. (1995) · Blood · doi:10.1182/blood.v86.11.4091.bloodjournal86114091 · Cited by 113 · see citing works

Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin‐11 and interleukin‐7

Ray, R. J., Paige, C. J., Furlonger, C. L., et al. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260715 · Cited by 112 · see citing works

Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III

Agnès, F., Shamoon, B., Dina, C., et al. (1994) · Gene · doi:10.1016/0378-1119(94)90021-3 · Cited by 112 · see citing works

FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress

Libura, M. A., Asnafi, V., Tu, A., Delabesse, É., Tigaud, I., Cymbalista, F., Griscelli, A. B., Villarèse, P., Solbu, G., Hagemeijer, A., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0162 · Cited by 109 · see citing works

Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene.

Lyman, S. D., James, L., Zappone, J., Sleath, P. R., Beckmann, M. P., & Bird, T. A. (1993) · PubMed · Cited by 107 · see citing works

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

Minami, Y., Kiyoi, H., Yamamoto, Y., Yamamoto, K., Ueda, R., Saito, H., & Naoe, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402558 · Cited by 106 · see citing works

Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.

Superti‐Furga, G., Gonfloni, S., Weijland, A., et al. (2000) · Nature Structural Biology · doi:10.1038/74041 · Cited by 106 · see citing works

Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study.

Uckun, F. M., Gaynon, P. S., Sensel, M. G., Nachman, J. B., Trigg, M., Steinherz, P. G., Hutchinson, R., Bostrom, B., Sather, H. N., & Reaman, G. H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2214 · Cited by 102 · see citing works

FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates

Lavagna-Sévenier, C., Marchetto, S., Birnbaum, D., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2400921 · Cited by 98 · see citing works

Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs.

Lyman, S. D., James, L., Escobar, S., et al. (1995) · PubMed · Cited by 96 · see citing works

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

Spiekermann, K., Bagrintseva, K., Schoch, C., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0953 · Cited by 95 · see citing works

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

Tse, K.-F., Allebach, J. P., Levis, M. J., Smith, B., Böhmer, F. D., & Small, D. (2002) · Leukemia · doi:10.1038/sj.leu.2402674 · Cited by 92 · see citing works

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

Zheng, R., Friedman, A. D., & Small, D. (2002) · Blood · doi:10.1182/blood-2002-03-0936 · Cited by 86 · see citing works

p85 Subunit of PI3 Kinase Does Not Bind to Human Flt3 Receptor, but Associates with SHP2, SHIP, and a Tyrosine-Phosphorylated 100-kDa Protein in Flt3 Ligand-Stimulated Hematopoietic Cells

Zhang, S., & Broxmeyer, H. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9959 · Cited by 84 · see citing works

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers

Disis, M. L., Rinn, K. J., Knutson, K. L., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2845 · Cited by 84 · see citing works

Genomic structure of human FLT3: implications for mutational analysis

Abu‐Duhier, F. M., Goodeve, A. C., Wilson, G. A., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02821.x · Cited by 83 · see citing works

The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal- cell-independent expansion and differentiation of human fetal pro-B cells in vitro

Namikawa, R., MO, M., de Vries, J. E., & Roncarolo, M. (1996) · Blood · doi:10.1182/blood.v87.5.1881.1881 · Cited by 83 · see citing works

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

Zhao, M., Kiyoi, H., Yamamoto, Y., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401680 · Cited by 81 · see citing works

Combined signaling through interleukin-7 receptors and flt3 but not c- kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells

Veiby, O., Lyman, S. D., & Jacobsen, S. E. W. (1996) · Blood · doi:10.1182/blood.v88.4.1256.bloodjournal8841256 · Cited by 80 · see citing works

Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c‐kit mutation Asp‐816 to Val

Sperr, W. R., Walchshofer, Horny, Födinger, Simonitsch, Fritsche‐Polanz, Schwarzinger, Tschachler, E., Sillaber, Hagen, et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01072.x · Cited by 77 · see citing works

Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase

Moriyama, Y., Tsujimura, T., Hashimoto, K., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3347 · Cited by 76 · see citing works

SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor

Marchetto, S., Fournier, E., Beslu, N., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401527 · Cited by 75 · see citing works

Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase.

Rottapel, R. K., Turck, C. W., Castéran, N., et al. (1994) · PubMed · Cited by 74 · see citing works

Mammalian cell transformation and aneuploidy induced by five bisphenols

Tsutsui, T., Tamura, Y., Suzuki, A., Hirose, Y., Kobayashi, M., Nishimura, H., Metzler, M., & Barrett, J. C. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000415)86:2 · Cited by 70 · see citing works

Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: Analysis of 19 patients from the BFM trials

Seidemann, K., Tiemann, M., Henze, G., Sauerbrey, A., M�ller, S., & Reiter, A. (1999) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199912)33:6 · Cited by 70 · see citing works

Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse.

Rosnet, O., Stephenson, D. A., Mattéi, M., et al. (1993) · PubMed · Cited by 67 · see citing works

Differential effects of Flk-2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells

Moore, T. A., & Zlotnik, A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.9.4187 · Cited by 60 · see citing works

The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor.

Lyman, S. D., Brasel, K., Rousseau, A. M., & Williams, D. E. (1994) · PubMed · Cited by 60 · see citing works

Acute Myeloid Leukemia With t(6;9) (p23;q34):Association With Myelodysplasia, Basophilia, and Initial CD34 Negative Immunophenotype

Alsabeh, R., Brynes, R. K., Slovak, M. L., et al. (1997) · American Journal of Clinical Pathology · doi:10.1093/ajcp/107.4.430 · Cited by 57 · see citing works

Multiple Point Mutation of N-ras and K-ras Oncogenes in Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Nakagawa, T., Saitoh, S., Imoto, S., Itoh, M., Tsutsumi, M., Hikiji, K., Nakamura, H., Matozaki, S., Ogawa, R., Nakao, Y., et al. (2009) · Oncology · doi:10.1159/000227023 · Cited by 56 · see citing works

Conditional Expression of Murine Flt3 Ligand Leads to Expansion of Multiple Dendritic Cell Subsets in Peripheral Blood and Tissues of Transgenic Mice

Manfra, D. J., Chen, S.-C., Jensen, K. K., Fine, J. S., Wiekowski, M., & Lira, S. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.2843 · Cited by 56 · see citing works

In vitro tumor-pulsed or in vivo Flt3 ligand–generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow–transplanted mice

Pawłowska, A., Hashino, S., McKenna, H. J., et al. (2001) · Blood · doi:10.1182/blood.v97.5.1474 · Cited by 54 · see citing works

Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line

Srinivasa, S. P., & Doshi, P. D. (2002) · Leukemia · doi:10.1038/sj.leu.2402367 · Cited by 52 · see citing works

Differentiation of chronic lymphocytic leukemia cells: correlation between the synthesis and secretion of immunoglobulins and the ultrastructure of the malignant cells

Rubartelli, A., Sitia, R., Zicca, A., et al. (1983) · Blood · doi:10.1182/blood.v62.2.495.495 · Cited by 49 · see citing works

Structural analysis of human and murine flt3 ligand genomic loci.

Lyman, S. D., Stocking, K. L., Davison, B. L., et al. (1995) · PubMed · Cited by 48 · see citing works

Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells.

Rogers, S., Bradbury, D. A., Kozlowski, R. Z., et al. (1994) · PubMed · Cited by 48 · see citing works

Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.

Dehmel, U., Zaborski, M., Meierhoff, G., et al. (1996) · PubMed · Cited by 47 · see citing works

Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.

Parajuli, P., Писарев, В. М., Sublet, J., Steffel, A., Varney, M. L., Singh, R. K., LaFace, D., & Talmadge, J. E. (2001) · PubMed · Cited by 45 · see citing works

Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells.

Hjertson, M., Sundström, C., Lyman, S. D., et al. (1996) · PubMed · Cited by 29 · see citing works

Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation

Morley, G. M., Uden, M., Gullick, W., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202646 · Cited by 29 · see citing works

FLT3/FLK‐2 (STK‐1) Ligand Does Not Stimulate Human Megakaryopoiesis In Vitro

Ratajczak, M. Z., Ratajczak, J., Ford, J. C., Kregenow, R., Marlicz, W. M., & Gewirtz, A. M. (1996) · Stem Cells · doi:10.1002/stem.140146 · Cited by 22 · see citing works

FLT‐3 ligand mobilizes hematopoietic primitive and committed progenitor cells into blood in mice

Ashihara, E., Shimazaki, C., Sudo, Y., et al. (1998) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1998.tb01003.x · Cited by 20 · see citing works

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628 · see citing works

The origin and evolution of mutations in acute myeloid leukemia

Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575 · see citing works

Myeloid Lineage Commitment from the Hematopoietic Stem Cell

Iwasaki, H., & Akashi, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.004 · Cited by 394 · see citing works

Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair

Sallmyr, A., Fan, J., & Rassool, F. V. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.036 · Cited by 285 · see citing works

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation

Tarighat, S. S., Santhanam, R., Frankhouser, D., Radomska, H. S., Lai, H., Anghelina, M., Wang, H., Huang, X., Alinari, L., Walker, A., et al. (2016) · Leukemia · doi:10.1038/leu.2015.308 · Cited by 169 · see citing works

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia <i>In Vitro</i> and <i>In Vivo</i>

Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52 · see citing works

Receptor tyrosine kinase-like orphan receptors ROR1/2: Insights into the mechanism of action, inhibition, and therapeutic potential

Rustagi, V., Nagar, G., Mittal, P., Singh, A. K., & Singh, I. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00018-1 · Cited by 2 · see citing works

Ectopic repression of receptor tyrosine kinase–like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial–mesenchymal transition

Xu, Y., Ma, Y., Pang, Y., et al. (2017) · Tumor Biology · doi:10.1177/1010428317701627 · Cited by 11 · see citing works

Receptor tyrosine kinases as therapeutic targets in cancer.

Hynes, N. E. (2005) · PubMed · Cited by 5 · see citing works

High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets

Müller‐Tidow, C., Schwäble, J., Steffen, B., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0954-03 · Cited by 118 · see citing works

v-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGFβ receptor

Anderson, D. H., & Ismail, P. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201780 · Cited by 27 · see citing works